| Literature DB >> 32858499 |
Maged Almezgagi1, Yu Zhang2, Kamal Hezam3, Emad Shamsan2, Mohammed Gamah4, Fadhl Al-Shaebi5, Abdul Baset Abbas6, Muhammad Shoaib2, Bassam Saif6, Ying Han7, Ruhan Jia7, Wei Zhang8.
Abstract
Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) and the active metabolite is rhein. It is a non-steroidal anti-inflammatory drug with unique pharmacological properties as anti-oxidant and anti-apoptosis. Diacerein has recently shown to have a potential role by mediating anti-inflammatory as well as anti-oxidant and anti-apoptosis in kidney injury, diabetes mullites, and a beneficial effect on pain relief. It may have a therapeutic role in cancer, ulcerative colitis, testicular injury and cervical hyperkeratosis. Furthermore, diacerein has a valuable addition in combination therapy as a synergetic agent. This review, the first of its kind, highlights the proposed roles of diacerein in osteoarthritis and discusses recent results supporting its emerging roles with a particular focus on how these new insights may facilitate the rational development of diacerein for targeted therapies in the future.Entities:
Keywords: Anti-apoptosis; Anti-inflammatory; Anti-oxidant; Cytokines; Diacerein
Mesh:
Substances:
Year: 2020 PMID: 32858499 DOI: 10.1016/j.biopha.2020.110594
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529